284 related articles for article (PubMed ID: 35108033)
1. Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges.
Hsu JY; Seligson ND; Hays JL; Miles WO; Chen JL
JCO Precis Oncol; 2022 Feb; 6():e2100211. PubMed ID: 35108033
[TBL] [Abstract][Full Text] [Related]
2. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
3. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
5. CDK4/6 inhibitors in breast cancer.
Dukelow T; Kishan D; Khasraw M; Murphy CG
Anticancer Drugs; 2015 Sep; 26(8):797-806. PubMed ID: 26053278
[TBL] [Abstract][Full Text] [Related]
6. CDK4/6 inhibitors in breast cancer - from
Saleh L; Wilson C; Holen I
Acta Oncol; 2020 Feb; 59(2):219-232. PubMed ID: 31671026
[No Abstract] [Full Text] [Related]
7. Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.
Piezzo M; Cocco S; Caputo R; Cianniello D; Gioia GD; Lauro VD; Fusco G; Martinelli C; Nuzzo F; Pensabene M; De Laurentiis M
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899866
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy.
Migliaccio I; Di Leo A; Malorni L
Curr Opin Oncol; 2014 Nov; 26(6):568-75. PubMed ID: 25188473
[TBL] [Abstract][Full Text] [Related]
9. Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.
Fang H; Huang D; Yang F; Guan X
Breast Cancer Res Treat; 2018 Apr; 168(2):287-297. PubMed ID: 29236235
[TBL] [Abstract][Full Text] [Related]
10. The application and prospect of CDK4/6 inhibitors in malignant solid tumors.
Du Q; Guo X; Wang M; Li Y; Sun X; Li Q
J Hematol Oncol; 2020 May; 13(1):41. PubMed ID: 32357912
[TBL] [Abstract][Full Text] [Related]
11. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA.
Perez M; Muñoz-Galván S; Jiménez-García MP; Marín JJ; Carnero A
Oncotarget; 2015 Dec; 6(38):40557-74. PubMed ID: 26528855
[TBL] [Abstract][Full Text] [Related]
13. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
14. Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss.
Lin DI; Hemmerich A; Edgerly C; Duncan D; Severson EA; Huang RSP; Ramkissoon SH; Connor YD; Shea M; Hecht JL; Ali SM; Vergilio JA; Ross JS; Elvin JA
Gynecol Oncol; 2020 May; 157(2):357-366. PubMed ID: 32156473
[TBL] [Abstract][Full Text] [Related]
15. Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma.
Yao J; Pollock RE; Lang A; Tan M; Pisters PW; Goodrich D; El-Naggar A; Yu D
Clin Cancer Res; 1998 Apr; 4(4):1065-70. PubMed ID: 9563903
[TBL] [Abstract][Full Text] [Related]
16. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.
Sobhani N; D'Angelo A; Pittacolo M; Roviello G; Miccoli A; Corona SP; Bernocchi O; Generali D; Otto T
Cells; 2019 Apr; 8(4):. PubMed ID: 30959874
[TBL] [Abstract][Full Text] [Related]
17. A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.
Guenther LM; Dharia NV; Ross L; Conway A; Robichaud AL; Catlett JL; Wechsler CS; Frank ES; Goodale A; Church AJ; Tseng YY; Guha R; McKnight CG; Janeway KA; Boehm JS; Mora J; Davis MI; Alexe G; Piccioni F; Stegmaier K
Clin Cancer Res; 2019 Feb; 25(4):1343-1357. PubMed ID: 30397176
[TBL] [Abstract][Full Text] [Related]
18. Targeting CDK4/6 pathways and beyond in breast cancer.
Ribnikar D; Volovat SR; Cardoso F
Breast; 2019 Feb; 43():8-17. PubMed ID: 30359883
[TBL] [Abstract][Full Text] [Related]
19. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathways: CDK4 inhibitors for cancer therapy.
Dickson MA
Clin Cancer Res; 2014 Jul; 20(13):3379-83. PubMed ID: 24795392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
